Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
The experts focused on cilta-cel when comparing the three FDA-approved treatments' efficacies, toxicities, and availability.
CAR T-cell therapy had the best OS and PFS, with BCMA-directed therapies also showing high rates of response.
This myeloma awareness month, clinicians are pushing for new treatment options to accelerate the journey towards a cure.
Within the first cycle of daratumumab-based therapy, all patients achieved serum free light chain reduction of 50% or more.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A study finds shortened overall survival with thrombotic events more severe in arterial thrombosis than venous thrombosis.
Advertisement
This orally available, selective inhibitor of XPO1 is the first agent of its kind to receive commercialization approval.
BCMA–directed CAR Ts were a vital advancement to RRMM treatment. Now, oncologists wonder which agent works best.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
Do IMID-containing quadruplet therapies represent both the present and future of myeloma treatment?
Linvoseltamab continues to be clinically evaluated as monotherapy and in combination therapy for relapsed or refractory MM.
Lenalidomide is indicated to treat myeloma in combination with dexamethasone and transfusion-dependent anemia due to MDS.
A retrospective study supported the safety of teclistamab and demonstrated a PFS benefit for patients with advanced myeloma.
A first-in-human multicenter phase I trial of this oral agent for relapsed or refractory disease is in progress.
Michael Tomasson, MD, discusses combining elranatamab with carfilzomib and dexamethasone in multiple myeloma.
Based on LINKER-MM1, FDA approval for linvoseltamab is under consideration.
Dr. Cole spoke about becoming an oncologist, his commitment to mitigating disparities for Black patients with MM, and more.
Blood Cancers Today spoke with several clinicians about how quadruplets are changing the myeloma treatment landscape.
Dr. Rakesh Popat joins the hosts of “Blood Cancer Talks” to highlight myeloma research presented at ASH 2024.
Dr. Patel discusses PFS and MRD negativity results from the CARTITUDE-4 trial of cilta-cel versus standard of care in MM.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.